Table 2 Diagnosis and treatment.
Items | Patients number (n = 49), n (%) |
|---|---|
Symptoms | |
Fever | 42 (85.7%) |
Abdominal pain | 4 (8.2%) |
No symptoms | 6 (12.2%) |
Imaging examinations, positive/examined number | |
CT | 49/49 (100%) |
Ultrasound | 22/37 (59.5%) |
Median time from symptoms to first CT (days), median (range) | 9 (0–55) days |
Median time from symptoms to first ultrasound, median (range) | 12 (0–115) days |
Mycological examinations, positive/examined number | |
1, 3-beta-D-glucan | 22/44 (50.0%) |
Candidiasis antibody | |
IgM | 6/17 (35.3%) |
IgG | 11/23 (47.8%) |
Liver function abnormalities, positive/examined number | |
Aspartate Aminotransferase | 11/48 (22.9%) |
Alanine Aminotransferase | 17/48 (35.4%) |
Gamma-Glutamyl Transferase | 34/48 (70.8%) |
Alkaline Phosphatase | 25/48 (52.1%) |
Total bilirubin | 9/48 (18.8%) |
Direct bilirubin | 11/48 (22.9%) |
Liver biopsy | 6 (12.2%) |
Proven candidiasis | 5 (10.2%) |
Candida tropicalis | 2 (4.1%) |
Candida albicans | 1 (2.0%) |
Undetermined species | 2 (4.1%) |
Median time from symptoms to biopsy, median (range) | 70 (10–132) days |
Diagnosis status | |
Possible | 41 (83.7%) |
Probable | 3 (6.1%) |
Proven | 5 (10.2%) |
Median time from symptoms to diagnosis, median (range) | 13.5 (0–132) days |
Concomitant bloodstream infection | |
Bacteremia | 6 (12.2%) |
